Per Thomas Lönngren

Per Thomas Lönngren discloses dealings in Egetis Therapeutics AB (publ) to Finansinspektionen. The record holds 5 filings, for trades running from 23 November 2021 to 17 May 2022.

Every open-market trade on record is a purchase: 4 purchases worth €78k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 1 share grant. 2022 to date brings 2 purchases and no sales.

In size, the median ticket on the buying side is €20k. Clusters matter here: 4 out of 4 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The newest entry dates from 20 May 2022: a share grant of €17k, in Egetis Therapeutics AB (publ). The last purchase on record was published on 25 February 2022, which is 1,717 days ago. The median gap between a trade and its publication by Finansinspektionen is 3 days. Under the Market Abuse Regulation, managers have three business days to notify their trades. Source: insider filings from Finansinspektionen. Past trades are no guide to future returns.